RESEARCH TRIANGLE PARK – Drug giant GSK has struck a $20 million one-year deal to gain access to genetics information from 23andMe. The news comes just ahead of GSK’s latest financial report which is due Wednesday.
The deal, which was announced early Monday, extends a five-year agreement between the two companies.
“We’ve had an incredibly successful collaboration with GSK over the past five years, and we are excited to continue our work together,” said Anne Wojcicki, CEO and Co-Founder, 23andMe, in the announcement. “With approximately 50 programs developed over the last five years, we are thrilled to work with GSK in discovering genetically validated targets. The continued relationship with GSK demonstrates the power of the 23andMe research platform to consistently produce novel insights for therapeutic development, rooted in human genetics.”
Read the full announcement online.
GSK employs thousands of people across the Triangle and is majority owner of ViiV Healthcare, which has a large operation in RTP.
